Ronald Park, Ambys Medicines CEO

Third Rock­'s Am­bys clos­es a megaround with the clin­ic still a ways off for its re­gen­er­a­tive cells for liv­er dis­ease

When Am­bys Med­i­cines, a Third Rock Ven­tures-backed re­gen­er­a­tive play, launched in 2018, it came with some se­ri­ous fan­fare for its liv­er dis­ease-fo­cused ap­proach. Now, af­ter years of qui­et de­vel­op­ment, the com­pa­ny has a new trough of mon­ey to play with as it slow­ly ap­proach­es the clin­ic.

Am­bys closed $107 mil­lion in to­tal Se­ries A fund­ing — with a $47 mil­lion ex­ten­sion add — Tues­day with a lead pro­gram cre­at­ing healthy ver­sions of liv­er cells still more than a year from the clin­ic, the biotech said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.